Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

Mark T. Reding, Ingrid Pabinger, Shadan Lalezari, Elena Santagostino, Maria Elisa Mancuso

Research output: Contribution to journalLetterpeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)e201-e204
Issue number4
StatePublished - Jul 1 2020

Bibliographical note

Funding Information:
Dr Inga Bayh of Bayer AG, Wuppertal, Germany, was responsible for the statistical analysis of this study. This study was supported by Bayer. Medical writing assistance was provided by Fishawack Communications Ltd., which was fully funded by Bayer.


  • BAY 94-9027
  • PROTECT VIII trial
  • bleeding
  • damoctocog alfa pegol
  • haemophilia A
  • target joint

Cite this